BioMarin Pharmaceutical (BMRN) reported Wednesday that its trial for Palynziq in adolescents with phenylketonuria showed a significant reduction in blood phenylalanine levels in patients aged 12 to 17.

The study met its primary efficacy endpoint, demonstrating that Palynziq was more effective than diet alone in lowering blood Phe levels. The safety results were consistent with the known profile of the medicine.

The company plans to present detailed findings at an upcoming medical meeting and will seek regulatory approval later this year to expand Palynziq's label for adolescent use.

Price: 68.00, Change: +0.06, Percent Change: +0.09